CLAIMS

1. A liquid suspension comprising:

- reparixin in an amount between 2% w/w and 13% w/w, preferably between 4% w/w and 13% w/w,
- xanthan gum in an amount between 0.15% w/w and 0.3% w/w,
- sucrose in an amount between 25% w/w and 55% w/w,
- polyvinylpyrrolidone in an amount between 1.8% w/w and 3.2% w/w,
- a water insoluble polymer in an amount between 2.25% w/w and 2.75% w/w.

2. The liquid suspension according to claim 1, wherein said water insoluble polymer is selected from microcrystalline cellulose and crospovidone.

3. The liquid suspension according to claim 1 or claim 2, wherein said water insoluble polymer is crospovidone, preferably in an amount of 2.5% w/w.

4. The liquid suspension according to any one of the preceding claims, further comprising an antifoaming agent, preferably a silicone derivative.

5. The liquid suspension according to claim 4, wherein said antifoaming agent is selected from:

- dimethicone in an amount between 0.5% w/w and 5% w/w, and
- simethicone in an amount between 0.003% w/w and 0.006% w/w, preferably in an amount of 0.005% w/w.

6. The liquid suspension according to any one of the preceding claims, further comprising a buffering agent, preferably selected from citrate buffer and phosphate buffer.

7. The liquid suspension according to claim 6, wherein said buffer is citrate buffer comprising monohydrate citric acid in an amount between 0.06% w/w and 0.6% w/w, preferably in an amount of 0.064% w/w, and dihydrate sodium citrate in an amount between 0.2% w/w and 0.3% w/w, preferably in an amount of 0.208% w/w.

8. The liquid suspension according to any one of the preceding claims, further comprising a preservative agent, preferably selected from potassium sorbate, sodium benzoate, methyl parabens and propyl parabens.

9. The liquid suspension according to claim 8, wherein said preservative agent is potassium sorbate in an amount between 0.1% w/w and 0.2% w/w, preferably in an amount of 0.15% w/w.

10. The liquid suspension according to any one of the preceding claims, wherein the amount of reparixin is between 2% w/w and 5.5% w/w, preferably between 3% w/w and 5.5% w/w, more preferably between 4.5% w/w and 5.5% w/w, more preferably between 4.7% w/w and 5.3% w/w, more preferably between 4.9% w/w and 5.1% w/w, even more preferably in an amount of 5% w/w.

11. The liquid suspension according to any one of claims 1 to 9, wherein the amount of reparixin is between 11.5% w/w and 12.5% w/w, preferably between 11.7% w/w and 12.3% w/w, more preferably between 11.9% w/w and 12.1% w/w, even more preferably in an amount of 12% w/w.

12. The liquid suspension according to claim 10, comprising:
- xanthan gum in an amount of 0.2% w/w,
- polyvinylpyrrolidone in an amount of 2% w/w.

13. The liquid suspension according to claim 11, comprising:
- xanthan gum in an amount of 0.2 % w/w,
- polyvinylpyrrolidone in an amount of 3% w/w.

14. The liquid suspension according to any one of the preceding claims, further comprising an aqueous solvent, preferably water, in an amount up to 100% w/w.

15. Use of the liquid suspension according to any one of the preceding claims, in the manufacture of a medicament for:

- the treatment of a disease or condition selected from psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome (ARDS), idiopathic fibrosis, glomerulonephritis, COVID-19, pneumonia caused by SARS-CoV-2 or a variant thereof,
- the prevention of diabetes or in delaying the onset and the progression of diabetes, preferably Type I diabetes,
- the prevention or treatment of seizures in an individual.

16. The liquid suspension according to any one of claims 1 to 14, for use in therapy.